A patient in New Zealand became the first person to receive a gene-editing serum to permanently lower levels of ‘bad’ LDL cholesterol, a major cause of heart disease worldwide. The procedure involved injecting an improved version of the gene-editing tool, CRISPR, to turn off a ‘bad’ gene by replacing a single letter in the liver DNA.
Leaders and changemakers of today face unique and complex challenges. The HEAD Foundation Digest features insights and opinions from those in the know addressing a wide range of pertinent issues that factor in a society’s development.
Informed opinions can inspire healthy discussions and open up our imagination to new possibilities. Interested in contributing? Write to us at info@headfoundation
Leaders and changemakers of today face unique and complex challenges. The HEAD Foundation Digest features insights and opinions from those in the know addressing a wide range of pertinent issues that factor in a society’s development.
Informed opinions can inspire healthy discussions and open up our imagination to new possibilities. Interested in contributing? Write to us at info@headfoundation
